JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT). Myeloid‐derived suppressor cells (MDSCs) have a protective effect on aGVHD via suppressing T cell function. However, the precise features and mechanism of JAK inhibitor‐mediated immune modulation on MDSCs subsets remain poorly understood.

[1]  A. Sharabi,et al.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy , 2022, Pharmacology & therapeutics.

[2]  E. Jiang,et al.  Regulatory T Cells in GVHD Therapy , 2021, Frontiers in Immunology.

[3]  Yu Lin,et al.  IL-17-producing γδT cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1+CD11b+ myeloid-derived suppressor cells , 2021, Bone Marrow Transplantation.

[4]  C. Bruker,et al.  Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. , 2021, Transplantation and cellular therapy.

[5]  R. Jenq,et al.  Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. , 2020, Blood.

[6]  L. Bullinger,et al.  Endothelial damage and dysfunction in acute graft-versus-host disease , 2020, Haematologica.

[7]  J. Magenau,et al.  Immunopathology and Biology Based Treatment of Steroid Refractory Graft-versus-Host Disease. , 2020, Blood.

[8]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[9]  N. Kröger,et al.  Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. , 2020, The Lancet. Haematology.

[10]  A. Lew,et al.  The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game , 2019, Front. Immunol..

[11]  J. Sierra,et al.  Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study , 2019, Bone Marrow Transplantation.

[12]  W. Guo,et al.  Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation , 2019, Cellular & Molecular Immunology.

[13]  R. Zeiser.  Advances in understanding the pathogenesis of graft‐versus‐host disease , 2019, British journal of haematology.

[14]  Xuan Zhou,et al.  Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma. , 2019, Oral oncology.

[15]  L. Ding,et al.  Myeloid-Derived Suppressor Cells Induce Podocyte Injury Through Increasing Reactive Oxygen Species in Lupus Nephritis , 2018, Front. Immunol..

[16]  G. Hill,et al.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. , 2018, Blood.

[17]  E. Holler,et al.  EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.

[18]  B. Blazar,et al.  Role of myeloid‐derived suppressor cells in allogeneic hematopoietic cell transplantation , 2017, Journal of leukocyte biology.

[19]  T. Brummer,et al.  MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation , 2017, Leukemia.

[20]  T. Zhu,et al.  The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury , 2017, Cell Death & Disease.

[21]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[22]  M. Huang,et al.  Circulating CD14+ HLA‐DR ‐/low myeloid‐derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft‐versus‐host disease , 2016, Cancer medicine.

[23]  Yang Zhao,et al.  Phenotype, development, and biological function of myeloid-derived suppressor cells , 2016, Oncoimmunology.

[24]  C. Lengerke,et al.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.

[25]  Simon C Watkins,et al.  The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. , 2015, Blood.

[26]  C. Recordati,et al.  Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects , 2015, Clinical Cancer Research.

[27]  M. Nagarkatti,et al.  Δ9‐Tetrahydrocannabinol‐mediated epigenetic modifications elicit myeloid‐derived suppressor cell activation via STAT3/S100A8 , 2015, Journal of leukocyte biology.

[28]  K. Zen,et al.  Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. , 2015, Journal of the American Society of Nephrology : JASN.

[29]  E. Choi,et al.  MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease , 2015, Mucosal Immunology.

[30]  P. Longoni,et al.  Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  P. Trikha,et al.  Signaling pathways involved in MDSC regulation. , 2014, Biochimica et biophysica acta.

[32]  C. Peschel,et al.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. , 2014, Blood.

[33]  Z. Qin,et al.  Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2 , 2014, The Journal of Immunology.

[34]  Q. Hu,et al.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. , 2013, The Journal of clinical investigation.

[35]  T. Glant,et al.  Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. , 2012, Arthritis and rheumatism.

[36]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[37]  S. Biswas,et al.  Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice , 2012, Journal of leukocyte biology.

[38]  P. Zabel,et al.  Myeloid‐derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties , 2011, Journal of leukocyte biology.

[39]  M. Fresno,et al.  Nuclear factor-κ B inducing kinase is required for graft-versus-host disease , 2010, Haematologica.

[40]  S. Wenzel,et al.  TLR4/MyD88-Induced CD11b+Gr-1intF4/80+ Non-Migratory Myeloid Cells Suppress Th2 Effector Function in the Lung , 2010, Mucosal Immunology.

[41]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[42]  T. Padhya,et al.  Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.

[43]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[44]  G. Bhagat,et al.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. , 2008, Cancer cell.

[45]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[46]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[47]  M. Fishman,et al.  Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.

[48]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[49]  S. Sebti,et al.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. , 2005, Cancer research.

[50]  D. Gabrilovich,et al.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.